Eli Lilly (LLY) EBITDA Margin (2009 - 2026)

Eli Lilly (LLY) posted EBITDA Margin of 47.98% for Q1 2026, up 3.96% quarter-over-quarter from 46.15% in Q4 2025, and up 660.0% year-on-year from 6.31% in Q1 2025.

Eli Lilly (LLY) EBITDA Margin (2009 - 2026) Analysis & Trends

Eli Lilly (LLY) has reported EBITDA Margin for 18 consecutive years, with 47.98% the latest figure, recorded in Q1 2026.

  • EBITDA Margin for Q1 2026 came in at 47.98%, up 660.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 46.29% (up 787.0% YoY), and the FY2025 annual result was 44.82%, up 890.0% from the prior year.
  • EBITDA Margin was 47.98% for Q1 2026 at Eli Lilly, up from 46.15% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 47.98% in Q1 2026 and troughed at 22.97% in Q1 2023.
  • Average EBITDA Margin over 5 years is 35.15%, with a median of 34.23% recorded in 2024.
  • Year-over-year, EBITDA Margin tumbled 993 bps in 2023 and surged 1150 bps in 2025.
  • Over 5 years, EBITDA Margin stood at 28.44% in 2022, then grew by 13 bps to 32.18% in 2023, then grew by 23 bps to 39.44% in 2024, then rose by 17 bps to 46.15% in 2025, then climbed by 4 bps to 47.98% in 2026.
  • Per Business Quant data, the three most recent EBITDA Margin figures were 47.98% in Q1 2026, 46.15% in Q4 2025, and 45.57% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 47.98%
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 26.44%
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 26.60%
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 18.85%
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -47.46%
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 30.94%
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.16%
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -286.83%
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -11.43%

Historic Data

Download Data
DateValue
Mar 31, 2026 47.98%
Dec 31, 2025 46.15%
Sep 30, 2025 45.57%
Jun 30, 2025 45.13%
Mar 31, 2025 41.38%
Dec 31, 2024 39.44%
Sep 30, 2024 38.05%
Jun 30, 2024 34.23%
Mar 31, 2024 29.88%
Dec 31, 2023 32.18%
Sep 30, 2023 36.06%
Jun 30, 2023 26.74%
Mar 31, 2023 22.97%
Dec 31, 2022 28.44%
Sep 30, 2022 25.05%
Jun 30, 2022 25.44%
Mar 31, 2022 32.91%
Dec 31, 2021 29.44%
Sep 30, 2021 30.40%
Jun 30, 2021 21.46%